Retrospective Analysis of Outcomes Following Percutaneous Cholecystostomy for Acute Cholecystitis

L L Kuan1,2, T Oyebola3, A Mavilakandy3

  • 1Department of Hepatobiliary and Pancreatic Surgery, University Hospitals of Leicester, NHS Trust, Gwendolen Road, Leicester, LE5 4PW, United Kingdom. kuan.lilian@gmail.com.

Insights

Percutaneous cholecystostomy (PC) offers a safe alternative for high-risk patients with acute cholecystitis. This procedure is effective for managing gallbladder inflammation and can be a valuable temporary measure before definitive treatment.

Area of Science:

  • Hepatobiliary surgery
  • Interventional radiology
  • Gastroenterology

Background:

  • Percutaneous cholecystostomy (PC) is a key intervention for acute cholecystitis in patients deemed too high-risk for surgical cholecystectomy.
  • This retrospective study evaluates the outcomes of PC in a high-risk patient cohort over a five-year period.

Purpose of the Study:

  • To assess the reasons for choosing PC over immediate surgery.
  • To determine the subsequent management and outcomes for patients treated with PC.
  • To identify the incidence of common bile duct stones (CBDS), PC-related complications, and 30-day mortality.

Main Methods:

  • Retrospective analysis of 96 patients undergoing PC for acute cholecystitis between January 2010 and December 2015.
  • Data collected from electronic databases, clinical notes, and imaging reports.
  • Evaluation of reasons for PC, definitive management, CBDS incidence, complications, and 30-day mortality.

Main Results:

  • 28.1% of patients had common bile duct stones (CBDS); 12.5% detected during PC cholangiogram.
  • High American Society of Anaesthesiologists (ASA) score (49%) and gallbladder empyema (29.1%) were primary indications for PC.
  • 25% of patients underwent interval cholecystectomy, and the 30-day in-hospital mortality rate was 16.7%.

Conclusions:

  • PC is a safe and effective salvage therapy for elderly, high-risk patients with comorbidities.
  • PC serves as a valuable temporizing measure, facilitating definitive treatment in high-risk individuals.
  • Vigilance for CBDS is crucial, necessitating further imaging (MRCP or check cholangiogram) to prevent recurrent sepsis in this vulnerable population.
Abstract